Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
An investigational drug for Dravet syndrome is showing promise in treating the progressive form of genetic epilepsy.
Data is still coming in from South Africa and other regions about the new Omicron variant of COVID-19. Early analysis suggests it causes less severe disease than other variants.
The latest updates from Mesoblast Limited’s Phase III trial on rexlemestrocel-L show that the drug provides the highest benefit when used in patients with certain types of chronic heart failure.
The approval of Keytruda also now includes stage III melanoma following complete resection for pediatric patients 12 years and up.
A major factor behind the success of the smallpox eradication campaign was political commitment and leadership.
The U.S. Food and Drug Administration is wrapping up 2021 with a fairly busy schedule for the month of December. Here’s a look at the first half of the month.
This afternoon, the U.S. Food and Drug Administration expanded the Emergency Use Authorization for Eli Lilly’s monoclonal antibody treatment combination of bamlanivimab and etesevimab.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
After Sobi agreed to be acquired by Advent International and GIC Special Investments, the deal has fallen through after AstraZeneca withheld its 8% stake from the buyout offer.
Two years into the COVID-19 pandemic, countries are reporting the fourth wave of rising cases, driven mainly by the Delta variant, although Omicron has everybody concerned. Here’s a look.
Researchers from Harvard University and the U.S. Department of Veterans Affairs (VA) found that the Moderna mRNA vaccine was slightly better than the Pfizer-BioNTech vaccine.
Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week’s ARASENS trial results should help pave the road.